The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics

(2010) Uma Mahadevan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

(2010) W. G. Dixon et al.   ARTHRITIS CARE & RESEARCH

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies

(2009) Eugene O. Major   Annual Review of Medicine

Pneumocystis jirovecipneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients

(2009) Yukiko Komano et al.   ARTHRITIS AND RHEUMATISM

Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis

(2009) Corey A. Siegel et al.   Clinical Gastroenterology and Hepatology

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

(2009) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

(2009) Andrea Cassinotti et al.   INFLAMMATORY BOWEL DISEASES

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

(2009) J.F. Rahier et al.   Journal of Crohns & Colitis

Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: Update

(2009) Ann Corken Mackey et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy

(2009) Hans Lindå et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

(2009) Frank Hoentjen et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

(2008) C. W. LEES et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis

(2008) Soko Setoguchi et al.   AMERICAN HEART JOURNAL

Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

(2008) Joachim Listing et al.   ARTHRITIS AND RHEUMATISM

Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality

(2008) Sarah Caspersen et al.   Clinical Gastroenterology and Hepatology

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

(2008) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology

Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

(2008) Murat Toruner et al.   GASTROENTEROLOGY

Natalizumab and PML: a risky business?

(2008) D. B Clifford   GUT

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

(2008) H Fidder et al.   GUT

Crohnʼs disease, hepatosplenic T-cell lymphoma and no biological therapy: Are we barking up the wrong tree?

(2008) Gordon Moran et al.   INFLAMMATORY BOWEL DISEASES

Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohnʼs disease

(2007) Ferenc Izbéki et al.   INFLAMMATORY BOWEL DISEASES